News
PCRX
47.23
-2.11%
-1.02
Will Pacira's (PCRX) Exparel Aid Growth Amid High Reliance?
Pacira's (PCRX) flagship product Exparel, along with other marketed products, is driving year over year growth. Pacira's efforts to expand Exparel label also holds promise.
Zacks · 11/18 18:38
Update: Pacira BioSciences Reports Higher Exparel Preliminary Net Product Sales in October; Wedbush Maintains Forecast
Update: Pacira BioSciences Reports Higher Exparel Preliminary Net Product Sales in October; Wedbush Maintains Forecast
MT Newswires · 11/15 07:04
Pacira BioSciences reports sales of $54.9M for October
Seekingalpha · 11/14 13:33
Pacira BioSciences Third Quarter 2022 Earnings: EPS Misses Expectations
Pacira BioSciences ( NASDAQ:PCRX ) Third Quarter 2022 Results Key Financial Results Revenue: US$167.5m (up 31% from 3Q...
Simply Wall St. · 11/09 10:14
Pacira BioSciences to Present at Two Healthcare Conferences in November
TAMPA, Fla., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the following two healthcare conferences: Jefferies London Healthcare Conference on Tuesday, ...
GlobeNewswire · 11/08 13:00
BMO Capital Maintains Market Perform on Pacira BioSciences, Lowers Price Target to $60
Benzinga · 11/07 13:43
--BMO Capital Adjusts Price Target on Pacira BioSciences to $60 From $66, Maintains Market Perform Rating
--BMO Capital Adjusts Price Target on Pacira BioSciences to $60 From $66, Maintains Market Perform Rating
MT Newswires · 11/07 11:02
--HC Wainwright Adjusts Price Target on Pacira BioSciences to $76 From $83, Maintains Buy Rating
--HC Wainwright Adjusts Price Target on Pacira BioSciences to $76 From $83, Maintains Buy Rating
MT Newswires · 11/04 11:17
HC Wainwright & Co. Maintains Buy on Pacira BioSciences, Lowers Price Target to $76
Benzinga · 11/04 10:53
--RBC Trims Pacira BioSciences' Price Target to $80 From $82, Keeps Outperform Rating
--RBC Trims Pacira BioSciences' Price Target to $80 From $82, Keeps Outperform Rating
MT Newswires · 11/04 09:30
--Wedbush Lowers Pacira BioSciences' Price Target to $88 From $94, Keeps Outperform Rating
--Wedbush Lowers Pacira BioSciences' Price Target to $88 From $94, Keeps Outperform Rating
MT Newswires · 11/04 08:09
Pacira Biosciences posts wider-than-expected loss
Seekingalpha · 11/03 18:51
Needham Maintains Buy on Pacira BioSciences, Lowers Price Target to $74
Benzinga · 11/03 17:34
Pacira (PCRX) Lags Q3 Earnings Estimates
Pacira (PCRX) delivered earnings and revenue surprises of -12.33% and 0.10%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 11/03 13:15
BRIEF-Pacira Biosciences Reports Quarterly Loss Per Share Of $0.02
Reuters · 11/03 12:46
Pacira BioSciences: Q3 Earnings Insights
Benzinga · 11/03 12:25
Pacira BioSciences GAAP EPS of -$0.02 misses by $0.39, revenue of $167.5M in-line
Seekingalpha · 11/03 12:09
Pacira BioSciences Q3 EPS $0.65 Misses $0.76 Estimate, Sales $167.47M Miss $168.89M Estimate
Benzinga · 11/03 12:02
Pacira BioSciences Reports Third Quarter 2022 Financial Results
-- Third quarter revenue of $167 million, increased 31% over prior year ---- Conference call today at 8:30 a.m. ET -- TAMPA, Fla., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioi...
GlobeNewswire · 11/03 12:00
Pacira BioSciences Q3 Non-GAAP Net Income Declines, Revenue Rises -- Shares Fall
Pacira BioSciences Q3 Non-GAAP Net Income Declines, Revenue Rises -- Shares Fall
MT Newswires · 11/03 10:14
More
Webull provides a variety of real-time PCRX stock news. You can receive the latest news about Pacira Biosciences Inc through multiple platforms. This information may help you make smarter investment decisions.
About PCRX
Pacira BioSciences, Inc. is a holding company for Pacira Pharmaceuticals, Inc. The Company is engaged in advancing a pipeline of products across a range of therapeutic areas that include acute postsurgical pain; acute and chronic osteoarthritis (OA), pain of the knee; low back and other areas; spasticity and stellate ganglion block of the sympathetic nerves. The company is developing interventions to address debilitating conditions involving the sympathetic nervous system. The Company's non-opioid treatments include EXPAREL (bupivacaine liposome injectable suspension), which is a long-acting, local analgesic; ZILRETTA (triamcinolone acetonide extended-release injectable suspension), which is an extended-release, intra-articular, corticosteroid injection indicated for OA knee pain, and Iovera, which is a novel handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve.